Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Neuraxpharm
Deal Size : Undisclosed
Deal Type : Agreement
Neuraxpharm and Pharmathen Enter into Agreement to Develop Long-acting Therapies
Details : The agreement aims to co-develop new long-acting injectable therapies within the psychiatry field under Pharmathen’s long-acting therapeutic technologies (LATT) program.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 12, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Neuraxpharm
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : Partners Group
Deal Size : $1,900.0 million
Deal Type : Acquisition
Partners Group to Acquire Pharmathen, a Leading European Pharmaceutical Company, from BC Partners
Details : Partners Group to Acquire Pharmathen, a Leading European Pharmaceutical Company, from BC Partners
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 19, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : Partners Group
Deal Size : $1,900.0 million
Deal Type : Acquisition
Lead Product(s) : Paliperidone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 07, 2018
Lead Product(s) : Paliperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MDX1303
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Department of Health and Human Services | National Institute of Allergy and Infectious Diseases | National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 23, 2010
Lead Product(s) : MDX1303
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Department of Health and Human Services | National Institute of Allergy and Infectious Diseases | National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Valortim
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : National Institute of Allergy and Infectious Diseases | National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
September 17, 2010
Lead Product(s) : Valortim
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : National Institute of Allergy and Infectious Diseases | National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
